# US 2016/0256387 A1 · Dual loaded liposomal pharmaceutical formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256387 A1
- Document ID: US20160256387A1
- Status: Published application
- Kind: A1
- Application number: 15/059,943
- Filed: 2016-03-03
- Published: 2016-09-08
- Earliest claimed: 2015-03-03
- Assignees: Cureport, Inc.
- Applicants: Cureport, Inc.
- Inventors: De-Min Zhu; Guoqiang Chen
- Web page: https://patentgrep.com/patent/US20160256387A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/1278: Post-loading, e.g. by ion or pH gradient
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition can include a plurality of liposomes comprising docetaxel and doxorubicin. In various embodiments, a liposome can include (i) an active pharmaceutical ingredient (API) comprising docetaxel and doxorubicin; (ii) a lipid layer comprising an unsaturated phospholipid, a cholesterol, a cationic lipid, and preferably a pegylated phospholipid; and (iii) an aqueous interior, wherein the docetaxel is in the lipid layer and the doxorubicin is crystallized in the aqueous interior. The liposomes can be used to treat a subject, for example, a human subject having cancer. The cancer can be, for example, a lung cancer, preferably non-small cell lung cancer (NSCLC), colon cancer, breast cancer, or liver cancer.

## Claims

### Claim 1

A liposome comprising:
an active pharmaceutical ingredient (API) comprising docetaxel and doxorubicin;
a lipid layer comprising an unsaturated phospholipid and a cholesterol; and
an aqueous interior,
wherein the docetaxel is in the lipid layer and the doxorubicin is crystallized in the aqueous interior.

### Claim 2 (depends on 1)

The liposome of claim 1, wherein the lipid layer consists essentially of the unsaturated phospholipid and cholesterol.

### Claim 3 (depends on 1)

The liposome of claim 1, wherein the lipid layer consists essentially of the unsaturated phospholipid, cholesterol, and a pegylated phospholipid.

### Claim 4 (depends on 1)

The liposome of claim 1, wherein the API consists essentially of docetaxel and doxorubicin.

### Claim 5 (depends on 1)

The liposome of claim 1, wherein the lipid layer comprises:
about 20-75% (molar) unsaturated phospholipid;
about 10-60% (molar) cholesterol; and
about 0-20% (molar) pegylated phospholipid.

### Claim 6 (depends on 1)

The liposome of claim 1, wherein:
the molar ratio of the lipid layer components:doxorubicin is about 100:1 to about 2:1; and
the molar ratio of the lipid layer components:docetaxel is about 100:1 to about 2:1.

### Claim 7 (depends on 1)

The liposome of claim 1, wherein the molar ratio of doxorubicin:docetaxel is about 10:1 to 1:10.

### Claim 8 (depends on 1)

The liposome of claim 1, wherein the unsaturated phospholipid comprises a polyunsaturated phospholipid or a monounsaturated phospholipid.

### Claim 9 (depends on 1)

The liposome of claim 1, wherein the cholesterol comprises a cationic cholesterol derivative.

### Claim 10 (depends on 1)

The liposome of claim 1, wherein the lipid layer further comprises a pegylated phospholipid.

### Claim 11 (depends on 1)

The liposome of claim 1, comprised in a pharmaceutical composition comprising a plurality of liposomes according to claim 1.

### Claim 12 (depends on 11)

The liposome of claim 11, wherein the plurality of liposomes are comprised in an intravenous formulation.

### Claim 13 (depends on 11)

The liposome of claim 11, wherein the Z-average particle size of the plurality of liposomes is about 10-200 nm.

### Claim 14 (depends on 11)

The liposome of claim 11, wherein, upon intravenous administration to a subject, at least about 10% of the composition is delivered to the liver.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A method comprising administering the liposome of claim 1 to a subject.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject has a cancer.

### Claim 19 (depends on 17)

The method of claim 17, wherein the cancer is a lung cancer; colon cancer; breast cancer; stomach cancer, esophagus cancer, prostate cancer, leukemia, head and neck cancer, pancreatic cancer, multiple myeloma, or liver cancer.

### Claim 20 (depends on 1)

A method of making the liposome of any of claim 1, comprising:
concurrently introducing a lipid solution of an unsaturated phospholipid, cholesterol, and docetaxel in ethanol through a first or plural inlet port of a manifold into a mixing chamber of the manifold and an aqueous solution through a second or plural inlet port of the manifold into the mixing chamber of the manifold into the mixing chamber, and the liposomes formed exit the mixing chamber through one or plural outlet chambers of the manifold, thereby making a plurality of liposomes; and
incubating the plurality of liposomes in a doxorubicin solution.

### Claim 21 (depends on 9)

The liposome of claim 9, wherein the pegylated phospholipid comprises a 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and wherein the pegylation is PEG 2000.

### Claim 22 (depends on 20)

The method of claim 20, wherein the first lipid solution further comprises a pegylated phospholipid.
